1. Name and Address of Reporting Person
   Zaks Tal Zvi
   (Last) C/O MODERNA, INC.
   (First) 200 TECHNOLOGY SQUARE
   (Middle) CAMBRIDGE MA 02139
   (Street)
   (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
   Moderna, Inc. [ MRNA ]

3. Date of Earliest Transaction (Month/Day/Year)
   10/19/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   10/19/2020

5. Relationship of Reporting Person(s) to Issuer
   Director
   Officer (give title below)
   Other (specify below)
   Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/19/2020</td>
<td>M(1)</td>
<td>5,000</td>
<td>A</td>
<td>$12.21</td>
<td>5,000</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/19/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>A</td>
<td>$19.15</td>
<td>15,000</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/19/2020</td>
<td>S(1)</td>
<td>5,695</td>
<td>D</td>
<td>$71.24</td>
<td>9,305</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/19/2020</td>
<td>S(1)</td>
<td>6,005</td>
<td>D</td>
<td>$71.92</td>
<td>3,300</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/19/2020</td>
<td>S(1)</td>
<td>3,100</td>
<td>D</td>
<td>$73.12</td>
<td>200</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/19/2020</td>
<td>S(1)</td>
<td>200</td>
<td>D</td>
<td>$73.81</td>
<td>0</td>
<td>D</td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$12.21</td>
<td>10/19/2020</td>
<td>M(1)</td>
<td>5,000</td>
<td>(6)</td>
<td>10/03/2027</td>
<td>Common Stock</td>
<td>5,000</td>
<td>$0</td>
<td>225,824</td>
<td>D</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$19.15</td>
<td>10/19/2020</td>
<td>M(1)</td>
<td>10,000</td>
<td>(7)</td>
<td>08/10/2026</td>
<td>Common Stock</td>
<td>10,000</td>
<td>$0</td>
<td>84,790</td>
<td>D</td>
</tr>
</tbody>
</table>

---

**Explanation of Responses:**

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.64 to $71.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.66 to $72.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.67 to $73.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.78 to $73.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
6. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
7. This option is fully vested and exercisable.

---

**Signature of Reporting Person**

Atorney-in-Fact

10/20/2020